HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 5 (2008), Issue 2 (February)

1. Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.
   Bioorg Med Chem, 16(2): 874-80. [Abstract] [Full-text]
2. Stereocontrolled synthesis and biological activity of two diastereoisomers of the potent HIV-1 protease inhibitor saquinavir.
   Bioorg Med Chem, 16(2): 902-8. [Abstract] [Full-text]
3. Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay.
   Anal Biochem, 374(1): 121-32. [Abstract] [Full-text]
4. Associations of insulin-like growth factor (IGF)-I and IGF-binding protein-3 with HIV disease progression in women.
   J Infect Dis, 197(2): 319-27. [Abstract] [Full-text]
5. Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment.
   Clin Vaccine Immunol, 15(2): 267-76. [Abstract] [Full-text]
6. Evaluation of the ultrasensitive human immunodeficiency virus type 1 (HIV-1) p24 antigen assay performed on dried blood spots for diagnosis of HIV-1 infection in infants.
   Clin Vaccine Immunol, 15(2): 388-91. [Abstract] [Full-text]
7. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals.
   Clin Vaccine Immunol, 15(2): 284-92. [Abstract] [Full-text]
8. Analysis of human immunodeficiency virus matrix domain replacements.
   Virology, 371(2): 322-35. [Abstract] [Full-text]
9. Association of alcohol abuse and injection drug use with immunologic and virologic responses to HAART in HIV-positive patients from urban community health clinics.
   J Community Health, 33(2): 69-77. [Abstract] [Full-text]
10. Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery.
    Immunology, 123(3): 378-89. [Abstract] [Full-text]
11. HIV-1 matrix protein p17 binds to monocytes and selectively stimulates MCP-1 secretion: role of transcriptional factor AP-1.
    Cell Microbiol, 10(3): 655-66. [Abstract] [Full-text]
12. Pseudodiploid genome organization AIDS full-length human immunodeficiency virus type 1 DNA synthesis.
    J Virol, 82(5): 2376-84. [Abstract] [Full-text]
13. Probing the structural states of human immunodeficiency virus type 1 pr55gag by using monoclonal antibodies.
    J Virol, 82(5): 2570-4. [Abstract] [Full-text]
14. Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction.
    J Virol, 82(5): 2528-42. [Abstract] [Full-text]
15. Interaction between the human immunodeficiency virus type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient gag membrane binding.
    J Virol, 82(5): 2405-17. [Abstract] [Full-text]
16. 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.
    J Virol, 82(5): 2367-75. [Abstract] [Full-text]
17. Heat shock perturbs TRIM5alpha restriction of human immunodeficiency virus type 1.
    J Virol, 82(5): 2575-9. [Abstract] [Full-text]
18. Probing dynamics of HIV-1 nucleocapsid protein/target hexanucleotide complexes by 2-aminopurine.
    Nucleic Acids Res, 36(3): 885-96. [Abstract] [Full-text]
19. Creating a ribonuclease T-tat that preferentially recognizes and hydrolyzes HIV-1 TAR RNA in vitro and in vivo.
    Nucleic Acids Res, 36(3): 963-9. [Abstract] [Full-text]
20. Identification of host proteins required for HIV infection through a functional genomic screen.
    Science, 319(5865): 921-6. [Abstract] [Full-text]
21. Human immunodeficiency virus 1 (HIV-1) virion infectivity factor (Vif) is part of reverse transcription complexes and acts as an accessory factor for reverse transcription.
    Virology, 372(1): 147-56. [Abstract] [Full-text]
22. HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes.
    Virology, 372(1): 136-46. [Abstract] [Full-text]
23. The packaging of human immunodeficiency virus type 1 RNA is restricted by overexpression of an RNA helicase DHX30.
    Virology, 372(1): 97-106. [Abstract] [Full-text]
24. TULA proteins bind to ABCE-1, a host factor of HIV-1 assembly, and inhibit HIV-1 biogenesis in a UBA-dependent fashion.
    Virology, 372(1): 10-23. [Abstract] [Full-text]
25. Effect of intrauterine HIV-1 exposure on the frequency and function of uninfected newborns' dendritic cells.
    Clin Immunol, 126(3): 243-50. [Abstract] [Full-text]
26. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis.
    Clin Immunol, 126(3): 235-42. [Abstract] [Full-text]
27. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells.
    Nat Immunol, 9(3): 301-9. [Abstract] [Full-text]
28. Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals.
    Clin Infect Dis, 46(6): 941-5. [Abstract] [Full-text]
29. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Mol Pharmacol, 73(3): 789-800. [Abstract] [Full-text]
30. Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous immunoglobulins.
    Immunology, 123(4): 508-18. [Abstract] [Full-text]
31. Hitting HIV where it hides.
    Retrovirology, 5: 15. [Abstract] [Full-text]
32. HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naïve and HAART-treated individuals.
    J Infect, 56(3): 219-25. [Abstract] [Full-text]
33. Selective downregulation of rhesus macaque and sooty mangabey major histocompatibility complex class I molecules by Nef alleles of simian immunodeficiency virus and human immunodeficiency virus type 2.
    J Virol, 82(6): 3139-46. [Abstract] [Full-text]
34. Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication.
    J Virol, 82(6): 2938-51. [Abstract] [Full-text]
35. Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccination.
    J Virol, 82(6): 2784-91. [Abstract] [Full-text]
36. Active beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells.
    J Virol, 82(6): 2813-20. [Abstract] [Full-text]
37. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.
    J Virol, 82(6): 2652-60. [Abstract] [Full-text]
38. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.
    J Virol, 82(6): 2975-88. [Abstract] [Full-text]
39. Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.
    J Virol, 82(6): 3078-89. [Abstract] [Full-text]
40. RNA structure modulates splicing efficiency at the human immunodeficiency virus type 1 major splice donor.
    J Virol, 82(6): 3090-8. [Abstract] [Full-text]
41. Human immunodeficiency virus type 1 Vpr induces cell cycle G2 arrest through Srk1/MK2-mediated phosphorylation of Cdc25.
    J Virol, 82(6): 2904-17. [Abstract] [Full-text]
42. Human immunodeficiency virus type 1 Nef recruits the guanine exchange factor Vav1 via an unexpected interface into plasma membrane microdomains for association with p21-activated kinase 2 activity.
    J Virol, 82(6): 2918-29. [Abstract] [Full-text]
43. Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference.
    J Virol, 82(6): 2895-903. [Abstract] [Full-text]
44. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors.
    J Virol, 82(6): 3125-30. [Abstract] [Full-text]
45. Chromatinized templates reveal the requirement for the LEDGF/p75 PWWP domain during HIV-1 integration in vitro.
    Nucleic Acids Res, 36(4): 1237-46. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.